Purposeful science. Lasting positive impact.
We are building a deep and expansive pipeline of rationally designed gene therapy product candidates, pioneering a shift to treat not only rare but also prevalent diseases. We apply our ART platform to develop first-in-class or
best-in-class product candidates using our proprietary capsids, promoters, and manufacturing approaches. We typically design multiple capsids and gene constructs with one as the lead and others as backups. We treat manufacturability as
a critical dimension, similar to efficacy and safety, aiming to define and control an initial manufacturing process that we can carry through the development path of the product candidate.
Our current internal pipeline focus is to develop gene therapies that treat nervous system, cardiac, and muscle diseases. In addition to establishing our own pipeline, we plan to benefit patients through strategic partnerships. For
example, through a collaboration with Vertex Pharmaceuticals, Affinia Therapeutics is combining our capsid design expertise with Vertex’s scientific, clinical, and regulatory capabilities to accelerate the development of genetic
medicines for people affected by Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and cystic fibrosis (CF).